Skip to Main Content

Paper Details

A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
Sci Transl Med
72
2016
Author NameAffiliation
Ernest TurroUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant, UK. Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Ernest TurroUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant, UK. Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Daniel GreeneUniversity of Cambridge, UK. Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Claire LentaigneImperial College Academic Health Sciences Centre, Imperial College London, UK. Imperial College Healthcare NHS Trust
Tadbir K BarianaUniversity College London Cancer Institute, Royal Free London NHS Foundation Trust
Sarah K WestburySchool of Clinical Sciences, University of Bristol
Anne M KellyUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant
Anne M KellyUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant
Jonathan StephensUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Christopher J PenkettUniversity of Cambridge, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Sofie AshfordUniversity of Cambridge, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Tony AttwoodUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Rémi FavierAssistance Publique-Hopitaux de Paris, Armand Trousseau Children Hospital, France. INSERM U1170
Myrto KostadimaUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant
Augusto RendonUniversity of Cambridge, UK. Genomics England Ltd.
Augusto RendonUniversity of Cambridge, UK. Genomics England Ltd.
Keith GomezUniversity College London Cancer Institute, Royal Free London NHS Foundation Trust
Wendy N ErberUniversity of Western Australia
Andrew D MumfordSchool of Clinical Sciences, University of Bristol
Andrew D MumfordSchool of Clinical Sciences, University of Bristol
Kathleen StirrupsUniversity of Cambridge, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
Kathleen StirrupsUniversity of Cambridge, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals
John R BradleyNational Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals, Cambridge University Hospitals NHS Foundation Trust
Frances Lucy RaymondNational Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals, Cambridge Institute for Medical Research, University of Cambridge
Mike LaffanImperial College Academic Health Sciences Centre, Imperial College London, UK. Imperial College Healthcare NHS Trust
Chris Van GeetCenter for Molecular and Vascular Biology, University of Leuven
Sylvia RichardsonMedical Research Council Biostatistics Unit, Cambridge Institute of Public Health
Kathleen FresonCenter for Molecular and Vascular Biology, University of Leuven
Kathleen FresonCenter for Molecular and Vascular Biology, University of Leuven
Willem H OuwehandUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals, Wellcome Trust Sanger Institute
Willem H OuwehandUniversity of Cambridge, UK. National Health Service (NHS) Blood and Transplant, UK. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals, Wellcome Trust Sanger Institute
  • 1 - 31

Datasets

Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink
Human Phenotype OntologyStandardized vocabulary of phenotypic abnormalities in human diseaseLink